Your session is about to expire
← Back to Search
Ociperlimab + Tislelizumab + Chemotherapy for Lung Cancer
Study Summary
This trial is testing a new cancer treatment combo vs. the current standard of care to see if the new combo is more effective and has fewer side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Arm A: Ociperlimab + tislelizumab histology-based chemotherapy
- Group 2: Arm B: Placebo + tislelizumab + histology-based chemotherapy
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this investigation into a new treatment protocol pioneering?
"Currently, 105 medical trials are ongoing for Ociperlimab across 426 cities and 45 countries. The initial trial of the drug began in 2017 under the sponsorship of BeiGene with 805 participants who successfully completed Phase 3 clinical testing. Since then, a total of 18337 studies have been concluded."
Has the Food and Drug Administration granted sanction to Ociperlimab?
"Ociperlimab's safety has been tested, but there is still no evidence of efficacy; thus our team at Power rated its safety a 2 on the 1-3 scale."
How many locations within the state are conducting this clinical investigation?
"This trial is currently being conducted at 10 sites, with locations in Henderson, Tyler and Los Angeles among others. To reduce travel inconveniences, it may be best to select a site that is closest to you if participating."
Are new participants being welcomed into the experiment?
"Currently, the clinical trial is in search of participants. It was first announced on November 16th 2021 and had its latest update on September 13th 2022."
Have there been any precedential experiments with Ociperlimab?
"Ociperlimab was initially studied in 2017 at Uniwersyteckie Centrum Kliniczne, and since then 18337 trials have been concluded. Currently 105 clinical tests are being conducted, the majority of which take place within Henderson, Nevada."
Share this study with friends
Copy Link
Messenger